Core Viewpoint - Magnesium Health is preparing for its second IPO attempt on the Hong Kong Stock Exchange, aiming to raise funds as a leading multi-payment platform in the pharmaceutical sector, with significant revenue growth and improving financial metrics [1][8]. Company Overview - Magnesium Health is the largest multi-payment platform in China for pharmaceuticals, ranking first in both the innovative smart drug solutions market and the innovative health insurance solutions market based on partnerships with pharmaceutical companies and processed health insurance policies [1][3]. Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenues of approximately RMB 20.35 billion, a 60% year-on-year increase, with a net loss of RMB 0.76 billion, narrowing by 70% [1][8]. - In the first ten months of 2025, revenues reached RMB 18.73 billion, a 30% year-on-year increase, but the net loss expanded to RMB 3.89 billion, a 366.93% increase in losses compared to the previous year [1][8]. - The gross profit margin for 2024 was 35.83%, while the gross profit for the first ten months of 2025 was RMB 6.01 billion, reflecting a 10.47% year-on-year increase [6][8]. Market Position - The company has served approximately 2 million patients, with a total medical expenditure of RMB 50.2 billion, and has partnerships with over 100 insurance companies, including all of China's top 20 insurers by premium income for 2024 [5][10]. - The innovative smart drug solutions market in China is projected to grow from RMB 521 billion in 2019 to RMB 910 billion by 2024, with a compound annual growth rate of 11.8% [10]. Product and Service Offerings - Magnesium Health has developed two major industry solutions: smart drug solutions and smart insurance solutions, aimed at providing comprehensive commercialization plans for pharmaceutical companies and end-to-end solutions for insurance companies [3][8]. - The company also offers consumer-facing services, including BluePass and a DTC pharmacy platform, designed to enhance patient experience and outcomes [3][8]. Competitive Landscape - Magnesium Health's market performance highlights its leading competitive position, with a significant number of partnerships and processed health insurance policies compared to competitors [13][15]. - The company has undergone multiple rounds of financing, raising over RMB 31.8 billion, with a post-money valuation of approximately RMB 116.8 billion following its latest financing round in December 2022 [19].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因依賴該等內容而引致的 任何損失承擔任何責任。 Shanghai MediTrust Health Technology Group Co., Ltd.* 上海鎂信健康科技集團股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，當中所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據經香港公司註冊處處長登記的本公司 招股章程作出投資決定；招股章程的文本將於發售期內向公眾刊發。 * 僅供識別 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件中 的資料作出任何 ...

Core Viewpoint - Magnesium Health, the largest provider of welfare insurance services in China, has submitted its IPO application to the Hong Kong Stock Exchange, with significant backing from major investors and banks [1][16]. Group 1: Company Overview - Magnesium Health was established in 2017 as a spin-off from Shanghai Pharmaceuticals and has since become the largest multi-payment platform in the pharmaceutical sector in China [1][17]. - The company has raised over 3 billion yuan in funding from investors including Ant Group and China Life Reinsurance [1][17]. - The revenue sources for Magnesium Health include smart pharmaceutical solutions for drug companies, smart insurance solutions for insurers, and services for consumers [1][17]. Group 2: Financial Performance - Revenue is projected to grow from 1.069 billion yuan in 2022 to 2.035 billion yuan in 2024, with smart pharmaceutical business revenue exceeding 1.207 billion yuan, accounting for nearly 60% of total revenue [1][17]. - Despite the revenue growth, the company has not yet achieved profitability, with cumulative losses exceeding 800 million yuan over three years [1][17]. Group 3: Business Model Concerns - Magnesium Health's business model focuses on creating a closed loop of "medical + pharmaceutical + insurance," but its connection with end consumers is weak, with only over 150,000 registered users on its direct-to-consumer platform [3][18]. - The company has not clearly defined customer acquisition scenarios and conversion paths for its core smart insurance and smart pharmaceutical businesses [19][21]. - Compared to competitors like Sipai Health and Yuanxin Technology, which have established direct patient engagement through physical pharmacies or online platforms, Magnesium Health's user engagement remains limited [3][19]. Group 4: Regulatory and Legal Issues - The company faces compliance risks, as it has been publicly named in regulatory investigations regarding its insurance and pharmaceutical collaboration models [12][27]. - Magnesium Health is involved in a long-standing commercial dispute with Beijing Tianxiao Technology, which has accused it of unfair competition and misappropriation of trade secrets [28][30]. - The ongoing legal issues may impact the company's reputation and operational stability, as the case has been formally investigated by law enforcement [28][29].

Group 1: Market Potential - The aging population and healthcare system reforms in China are creating significant opportunities in the healthcare market, attracting substantial capital interest [1] - In Western countries, aging demographics and increased healthcare demands have led to sustained high growth in the performance of leading healthcare companies, which is expected to be replicated by quality listed companies in China's healthcare sector [1] Group 2: Investment Opportunities - Investors are focusing on companies that can integrate payers, service providers, and product suppliers to build a "Chinese version of UnitedHealth" ecosystem, as many platforms currently rely heavily on membership fees and online consultation charges, leading to a lack of customer stickiness [3] - Shanghai Meixin Health Technology Group Co., Ltd. (Meixin Health), which went public in Hong Kong in June, is gaining attention for its "medical + pharmaceutical + insurance" service model, addressing payment challenges faced by patients, insurance companies, and pharmaceutical firms [3] Group 3: Business Model and Solutions - Meixin Health has become China's largest multi-payment platform for pharmaceuticals, saving patients approximately 6.7 billion yuan in out-of-pocket expenses and driving sales growth for innovative drugs [4][6] - The company offers intelligent pharmaceutical and insurance solutions that better integrate resources from pharmaceutical companies and insurance firms, ensuring sustainable business development [4] Group 4: Financial Performance - Meixin Health's revenue is projected to grow from 1.069 billion yuan in 2022 to 2.035 billion yuan in 2024, with gross profit increasing from 332 million yuan to 729 million yuan during the same period, indicating a steady growth trend [6] - The company is enhancing its AI capabilities to improve operational efficiency and reduce costs, establishing a differentiated barrier with its "payment + service + AI" model [6]

Group 1 - The Hong Kong pharmaceutical sector has seen a significant surge in IPO activity, with 26% of the 118 active listings in Q1 2023 coming from the medical and pharmaceutical industry [1] - In June 2023, 15 healthcare companies submitted listing applications to the Hong Kong Stock Exchange, indicating unprecedented enthusiasm for IPOs in the sector [1] - The recovery of the Hong Kong biopharmaceutical sector is attributed to relaxed listing rules, global funds re-evaluating Chinese innovative assets, and favorable policies, which together have restored market confidence [3] Group 2 - The payment structure for innovative drugs and medical devices in China is expected to become more balanced and diversified by 2030, with the total payment amount for innovative drug solutions projected to grow from 91 billion yuan in 2024 to 243.3 billion yuan in 2030, reflecting a compound annual growth rate of 17.8% [3] - The commercial health insurance market is anticipated to double by 2030 compared to 2024, with premiums expected to exceed 1.35 trillion yuan [3] Group 3 - The industry faces common challenges, including patient payment difficulties, limited insurance product offerings, and restricted pharmaceutical channels, which need to be addressed for further development [4] - Shanghai Meixin Health Technology Group aims to bridge the gap between patients, pharmaceutical companies, and insurance firms through its "Smart Drug Solutions" and "Smart Insurance Solutions," enhancing the flow of drugs from development to market [4] Group 4 - Meixin Health's revenue is projected to grow rapidly from 1.069 billion yuan in 2022 to 2.035 billion yuan in 2024, with a compound annual growth rate of 38% [5] - Despite strong revenue growth, Meixin Health reported net losses of 446 million yuan in 2022, 288 million yuan in 2023, and a reduced loss of 76 million yuan in 2024, indicating a positive trend in financial performance [5] Group 5 - The company has successfully reduced its operating expenses from 78% of total revenue in 2022 to 41.3% in 2024, while also optimizing R&D expenditures [5] - The upcoming implementation of the commercial insurance innovative drug catalog in 2025 is expected to provide further policy support for Meixin Health's strategic positioning in the diversified medical payment sector [6]

Group 1 - The core viewpoint of the article is that Shanghai Meixin Health Technology Group Co., Ltd. is seeking to go public in Hong Kong, highlighting its position as a leading multi-payment platform in the pharmaceutical industry and its significant revenue growth potential [1][2][3]. Group 2 - Meixin Health's revenue for 2022, 2023, and 2024 is projected to be RMB 1.069 billion, RMB 1.255 billion, and RMB 2.035 billion respectively, indicating a compound annual growth rate of approximately 38% over the three years [1][2]. - The company reported a narrowing net loss of RMB 0.76 billion in 2024, down from RMB 2.88 billion in 2023 and RMB 4.46 billion in 2022, primarily due to substantial investments in infrastructure and technology [2][3]. - As of December 31, 2024, Meixin Health has served approximately 393 million insurance policies and collaborated with over 140 pharmaceutical companies and more than 90 insurance companies [2][3]. Group 3 - The demand for innovative pharmaceutical payment solutions and health insurance services is growing, with the market for innovative pharmaceutical solutions expected to increase from RMB 521 billion in 2019 to RMB 910 billion in 2024, and projected to reach RMB 2.433 trillion by 2030 [4]. - The commercial health insurance premium in China is anticipated to rise from RMB 2.429 trillion in 2019 to RMB 4.3 trillion in 2024, with a projected compound annual growth rate of 21.0% from 2024 to 2030 [4]. - The company plans to deepen existing partnerships with pharmaceutical companies and insurance providers while actively seeking new collaboration opportunities to enhance its influence in the healthcare ecosystem [4][5]. Group 4 - Specific plans include collaborating with pharmaceutical companies to include more innovative products in insurance offerings, developing customized insurance products with insurance providers to meet diverse patient needs, and leveraging patient insights to design policies that alleviate financial burdens [5][6]. - Meixin Health aims to launch a consumer-centric one-stop service platform called "Yima Zhifu," integrating resources from pharmaceuticals, healthcare, and insurance to provide more payment options and enhance user experience [6].

Group 1 - The Hong Kong Stock Exchange (HKEX) has seen a significant increase in financing, reaching 884 billion HKD in the first half of 2025, surpassing the total for the entire year of 2024 [1] - The biopharmaceutical sector is experiencing a surge, with over 20 Class 1 innovative drugs approved by the National Medical Products Administration in the first five months of 2025, setting a record for the past five years [2] - As of June 30, 2025, southbound capital net purchases reached 731.19 billion HKD, nearing the total for the entire year of 2024, with over 120 billion HKD directed towards the healthcare sector [2] Group 2 - Several biopharmaceutical companies are rushing to file for IPOs, including traditional pharmaceutical firms and platform players like Meixin Health, which focuses on multi-payment solutions in the pharmaceutical sector [5] - Meixin Health is positioned as a pioneer in the pharmaceutical multi-payment space, leveraging AI technology to reconstruct the value chain among pharmaceutical companies, insurance, and patients [5][6] - The Chinese market for innovative pharmaceuticals is projected to undergo a significant transformation in payment structures, with a forecasted compound annual growth rate of 17.8% from 2024 to 2030 [10] Group 3 - Recent policies, such as the "Measures to Support the High-Quality Development of Innovative Drugs," aim to enhance the integration of medical, insurance, and pharmaceutical data, improving the precision and competitiveness of insurance products [7] - The introduction of a commercial health insurance innovative drug directory marks a significant step in building a multi-payment system for innovative pharmaceuticals in China [7][8] - The current imbalance in payment structures, with a patient self-payment ratio of 48.5% in 2024, indicates a substantial opportunity for reform in the payment system [9] Group 4 - Meixin Health's AI-driven platform capabilities, such as the mind42.ai system, enhance insurance claims processing and operational efficiency, significantly reducing claim review times [17] - The company has developed a comprehensive supply chain network, MediTrust Rx, to ensure timely access to innovative treatments for patients [19] - Meixin Health's platform, "Yima Zhifu," simplifies the payment process for patients, allowing for seamless transactions in medical settings [23][25] Group 5 - The company has established a dual-driven platform strategy, offering "Smart Drug Solutions" for pharmaceutical companies and "Smart Insurance Solutions" for insurers, aiming to enhance market penetration and product innovation [26] - Meixin Health has served approximately 1.6 million patients, with a total medical expenditure value of 39.7 billion RMB as of the end of 2024 [28] - The company has successfully covered 40% of China's listed Class 1 innovative drugs, including over 60% of oncology-related medications, highlighting its critical role in the innovative pharmaceutical payment landscape [28] Group 6 - Meixin Health's innovative technology platform is reshaping the efficiency of connections within the healthcare ecosystem, creating a self-reinforcing cycle of growth and collaboration [30] - The company is positioned to become a key infrastructure player in the upgrade of China's medical payment systems, as commercial health insurance evolves from a supplementary role to a necessary component [31] - With ongoing capital support, Meixin Health is poised for significant growth and value realization in the future [32]

Core Viewpoint - The IPO enthusiasm in the Hong Kong market is rising, with Shanghai Meixin Health Technology Group Co., Ltd. planning to go public, aiming to transform China's medical payment system [1][2]. Company Overview - Shanghai Meixin Health is the largest pharmaceutical multi-payment platform in China, focusing on addressing financing and payment challenges faced by patients, insurers, and pharmaceutical companies [1]. - As of December 31, 2024, the company has served approximately 393 million insurance policies and collaborated with over 140 pharmaceutical companies and more than 90 insurers [1]. Financial Performance - Revenue from 2022 to 2024 was reported as follows: 1.069 billion yuan, 1.255 billion yuan, and 2.035 billion yuan, with a compound annual growth rate of approximately 38% [2]. - Despite revenue growth, the company reported net losses of 446 million yuan, 288 million yuan, and 79 million yuan for the same period, indicating a need for a sustainable profit model [2]. IPO Challenges - The path to IPO has been complicated by legal disputes, including allegations of trade secret infringement from a former partner, which have delayed the listing process [3][4]. - Regulatory scrutiny has increased, with the China Banking and Insurance Regulatory Commission highlighting issues in the short-term health insurance sector, affecting Meixin's product offerings and profitability [4][6]. Market Competition - The medical payment sector is becoming increasingly competitive, with Meixin Health relying heavily on partnerships with pharmaceutical companies and insurers [6]. - The company faces pressure to enhance service quality and innovation to maintain its market position [6]. Future Outlook - Meixin Health plans to deepen collaborations with pharmaceutical companies and insurers, investing in an integrated payment platform to optimize healthcare payments and services [7]. - The company aims to address structural imbalances in the medical payment system while navigating regulatory challenges and profitability issues [8].

Core Viewpoint - Magnesium Health aims to transform China's medical payment system and has become the largest multi-payment platform in the country, with a valuation of 11.6775 billion RMB after the last round of financing before its IPO [1][11]. Group 1: Company Overview - Founded in 2017, Magnesium Health focuses on addressing financing and payment challenges faced by patients, insurers, and pharmaceutical companies [2]. - As of December 31, 2024, Magnesium Health has saved patients approximately 6.7 billion RMB in out-of-pocket expenses through its solutions [2]. - The company has developed two major industry solutions: Smart Drug Solutions and Smart Insurance Solutions, ranking first in China for innovative drug and health insurance solutions [2][4]. Group 2: Market Position and Reach - By the end of 2024, Magnesium Health has served around 1.6 million patients, with a total medical expenditure GPV of 39.7 billion RMB [4]. - The company collaborates with over 90 insurance companies, including the top 20 in China by premium income, and more than 140 pharmaceutical companies, covering 40% of listed Class 1 new drugs in China [4]. Group 3: Financial Performance - Revenue for Magnesium Health from 2022 to 2024 was 1.069 billion RMB, 1.255 billion RMB, and 2.035 billion RMB, respectively, with gross profit margins of 31.1%, 36.8%, and 35.8% [7]. - The adjusted net losses for the same period were 447 million RMB, 290 million RMB, and 80 million RMB, showing a significant narrowing trend in loss rates [8]. Group 4: Industry Growth Potential - The Chinese healthcare market is expected to continue growing, driven by favorable government policies, an aging population, and increasing public health awareness [9]. - The innovative drug and medical device market in China is projected to grow from 92.3 billion RMB in 2019 to 162 billion RMB in 2024, with a compound annual growth rate (CAGR) of 11.9% [9]. Group 5: Future Plans and Use of IPO Proceeds - The net proceeds from the IPO will be used to expand and upgrade services for pharmaceutical companies and insurers, develop the integrated payment platform, and enhance key infrastructure [11].